Department of Radiation Oncology, Perelman School of Medicine, Philadelphia, PA, USA.
Department of Radiation Oncology, Tel Aviv Medical Center, Tel Aviv, Israel.
Radiat Oncol. 2023 Aug 11;18(1):133. doi: 10.1186/s13014-023-02318-0.
With advances in understanding liver tolerance, conformal techniques, image guidance, and motion management, dose-escalated radiotherapy has become a potential treatment for inoperable hepatocellular carcinoma (HCC). We aimed to evaluate the possible impact of biologically effective dose (BED) on local control and toxicity among patients with HCC.
Patients treated at our institution from 2009 to 2018 were included in this retrospective analysis if they received definitive-intent radiotherapy with a nominal BED of at least 60 Gy. Patients were stratified into small and large tumors using a cutoff of 5 cm, based on our clinical practice. Toxicity was assessed using ALBI scores and rates of clinical liver function deterioration.
One hundred and twenty-eight patients were included, with a mean follow-up of 16 months. The majority of patients (90.5%) had a good performance status (ECOG 0-1), with Child-Pugh A (66.4%) and ALBI Grade 2 liver function at baseline (55.4%). Twenty (15.6%) patients had a local recurrence in the irradiated field during the follow-up period. Univariate and multivariate Cox proportional hazard analyses showed that only BED significantly predicted local tumor recurrence. Higher BED was associated with improved local control in tumors with equivalent diameters over 5 cm but not in smaller tumors. There was no difference in liver toxicity between the low and high-dose groups.
Higher radiotherapy dose is associated with improved local control in large tumors but not in tumors smaller than 5 cm in diameter. High-dose radiotherapy was not associated with increased liver toxicity.
随着对肝脏耐受性、适形技术、图像引导和运动管理的理解的进步,剂量递增放疗已成为不可切除肝癌(HCC)的一种潜在治疗方法。我们旨在评估 HCC 患者的生物有效剂量(BED)对局部控制和毒性的可能影响。
如果患者在我们机构接受了明确意图的放疗,且名义 BED 至少为 60Gy,则将其纳入本回顾性分析。根据我们的临床实践,患者根据肿瘤大小(5cm)分为小肿瘤和大肿瘤。采用 ALBI 评分和临床肝功能恶化率评估毒性。
共纳入 128 例患者,平均随访 16 个月。大多数患者(90.5%)具有良好的体能状态(ECOG 0-1),基线时 Child-Pugh A(66.4%)和 ALBI 分级 2 级肝功能(55.4%)。在随访期间,20 例(15.6%)患者在照射野内发生局部复发。单变量和多变量 Cox 比例风险分析表明,只有 BED 显著预测局部肿瘤复发。在直径大于 5cm 的肿瘤中,较高的 BED 与局部控制改善相关,但在直径较小的肿瘤中则没有。低剂量组和高剂量组之间的肝毒性无差异。
较高的放疗剂量与大肿瘤的局部控制改善相关,但与直径小于 5cm 的肿瘤无关。高剂量放疗与增加的肝毒性无关。